Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor

Journal of Immunotherapy

Volumn 38, Issue 3, 2015, Pages 127-135

  Wang, Xiuyan ^a,b   Olszewska, Malgorzata ^a   Qu, Jinrong ^a   Wasielewska, Teresa ^a   Bartido, Shirley ^a   Hermetet, Gregory ^a   Sadelain, Michel ^b,c   Rivière, Isabelle ^a,b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Molecular Pharmacology and Chemistry Program   (United States)

^c PALL CORPORATION   (United States)

Author keywords

fixed bed bioreactor; g retroviral vector; high vector titers; high vector yields; Scalable clinical grade vector manufacture

Indexed keywords

RETROVIRUS VECTOR;

ARTICLE; CELL DENSITY; CELL ENGINEERING; CELL GROWTH; CELL LINE; FIXED BED REACTOR; GOOD MANUFACTURING PRACTICE; LARGE SCALE PRODUCTION; PACKAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROCESS OPTIMIZATION; SCALE UP; ANIMAL; BATCH CELL CULTURE; BIOREACTOR; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; GIBBON APE LEUKEMIA VIRUS; HEK293 CELL LINE; HUMAN; METABOLISM; PROCEDURES; RETROVIRIDAE; STANDARDS; T LYMPHOCYTE; TRANSFORMED CELL LINE;

ANIMALS; BATCH CELL CULTURE TECHNIQUES; BIOREACTORS; CELL LINE, TRANSFORMED; GENETIC VECTORS; HEK293 CELLS; HUMANS; LEUKEMIA VIRUS, GIBBON APE; RETROVIRIDAE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 84925631447     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000072     Document Type: Article

References (24)

1. Przybylowski M, Hakakha A, Stefanski J, et al. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. Gene Therapy. 2006;13:95-100.
2. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817-4828.
3. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra138:1-9.
4. Davila ML, Bouhassira DC, Park JH, et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol. 2014;99:361-371.
5. Miller AD, Garcia JV, von Suher N, et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol. 1991;65:2220-2224.
6. Hollyman D, Stefanski J, Przybylowski M, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immun-other. 2009;32:169-180.
7. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13:5426-5435.
8. Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol. 2002;20:70-75.
9. Ghani K, Wang X, de Campos-Lima PO, et al. Efficient human hematopoietic cell transduction using RD114-and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media. Hum Gene Ther. 2009;20:966-974.
10. Lamers CH, van Elzakker P, Luider BA, et al. Retroviral vectors for clinical immunogene therapy are stable for up to 9 years. Cancer Gene Ther. 2008;15:268-274.
11. Schilz AJ, Kuhlcke K, Fauser AA, et al. Optimization of retroviral vector generation for clinical application. J Gene Med. 2001;3:427-436.
12. Suerth JD, Schambach A, Baum C. Genetic modification of lymphocytes by retrovirus-based vectors. Curr Opin Immunol. 2012;24:598-608.
13. Rivat C, Santilli G, Gaspar HB, et al. Gene therapy for primary immunodeficiencies. Hum Gene Ther. 2012;23:668-675.
14. Merten OW, Cruz PE, Rochette C, et al. Comparison of different bioreactor systems for the production of high titer retroviral vectors. Biotechnol Prog. 2001;17:326-335.
15. Reeves L, Smucker P, Cornetta K. Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience. Hum Gene Ther. 2000;11:2093-2103.
16. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra225:1-10.
17. Rigg RJ, Chen J, Dando JS, et al. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. Virology. 1996;218:290-295.
18. Forestell SP, Dando JS, Chen J, et al. Novel retroviral packaging cell lines: complementary tropisms and improved vector production for efficient gene transfer. Gene Ther. 1997;4:600-610.
19. Palu G, Parolin C, Takeuchi Y, et al. Progress with retroviral gene vectors. Rev Med Virol. 2000;10:185-202.
20. Mangeot PE, Negre D, Dubois B, et al. Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J Virol. 2000;74:8307-8315.
21. Olsen JC, Sechelski J. Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA. Hum Gene Ther. 1995;6:1195-1202.
22. Shen BQ, Clarke MF, Palsson BO. Kinetics of retroviral production from the amphotropic PsiCRIP murine producer cell line. Cytotechnology. 1996;22:185-195.
23. Gerin PA, Gilligan MG, Searle PF, et al. Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum-and protein-free medium. Hum Gene Ther. 1999;10:1965-1974.
24. McTaggart S, Al-Rubeai M. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line. Biotechnol Prog. 2000;16:859-865.